AzTrials
AzTrials

CoxarthrosisPrimorisNCT01326832

10 Year Clinical Evaluation of Primoris Hip Component

An observational study of Coxarthrosis, run by Zimmer Biomet at 2 sites in Denmark.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Using the traditional and hitherto used uncemented hip prostheses achieved good clinical results, but one of the drawbacks is the risk of fracture in the femoral shaft in indbankning of the prosthesis (1-2%). Read more about this study

Who is it for?
Ages 18 to 65 years
Conditions the study is for
Coxarthrosis
What is being tested?
Primoris
Type of treatment
Medical device
How many people
350 participants
Where
2 sitesDenmark
Study dates
Sep 2011to Dec 2024
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: younger patients with coxarthrosis

Who may be able to join

  • younger OA patients with good bonestock

Who cannot join

  • Patients who do not understand the given information to patients
  • Competing disorder requiring treatment with anti-inflammatory drugs (NSAIDs, steroids, cytostatics).
  • Estimated remaining life expectancy < 10 years
  • Rheumatoid arthritis or other arthritis (eg psoriatic arthritis).
  • Previous surgery on relevant hip.
  • Pain Normative and disabling osteoarthritis of the ipsilateral knee.
Show all 17Show fewer
  • Co-mobiditet (ASA-group 3-5).
  • Neurological disorder which compromises the motor skills and rehabilitation courses.
  • Pregnancy.
  • Osteoarthritis secondary to Calvé-Legg-Perthes' disease and juvenile epifysiolysis coxae.
  • Acetabular dysplasia and secondary subluxation (Crowie grade II to IV).
  • Previously established osteoporosis or osteoporosis detected by current DEXA scan.
  • Ongoing treatment with osteoporosis medications (calcium and vitamin D, bisphosphonates, estrogen receptor modulating agents and parathyroid hormone, etc.).
  • Aseptic caputnekrosis (post-traumatic, idiopathic).
  • Deform the femoral neck (femoral length, measured medially ≤ 15 mm)
  • Varus or valgus deformity in proximal femur inc. femoral (Collum angel < 125 ° or > 145 °.)
  • Retroversion or anteversion femur.

Trial locations and contacts

2 sites in 1 country.

Denmark2 sites
  • Aalborg University Hospital

    Aalborg

  • Veijle Hospital

    Vejle

Other trials in Denmark

About this study

Official title: Prospective Study for Evaluation of Proximally Anchored (Metaphysis) Cementless Femoral Component for Total Hip Arthroplasty. 10 Year Clinical Evaluation,DXA and RSA Follow-up of Primoris® Femoral Component.

Using the traditional and hitherto used uncemented hip prostheses achieved good clinical results, but one of the drawbacks is the risk of fracture in the femoral shaft in indbankning of the prosthesis (1-2%). In addition, the bone scan demonstrated that in the years after surgery dropped almost 30% of bone mass in the femoral shaft. This bone loss increases the risk that in the years after surgery, the increased risk of fractures around the prosthesis and in addition to impeding the described bone replacement prosthesis later.

The newly developed prosthesis is anchored in the femoral neck and thus not involve the femoral shaft. This ensures a more physiological or normal weight transfer to the femur bone.

This contributes to bone mass in long large extent preserved in the years after surgery, so you have a better opportunity later to make a new prosthesis surgery with good results. The new prosthesis should be capable of simultaneously reducing the incidence of thigh pain in the first year after surgery.'

Read the detailed description

By insertion of artificial hip joints in young and middle aged are often used so-called uncemented technique in which the prosthesis is fixed to the bone without the use of bone cement. Anchoring happens when the bone cells grow into the prosthesis porous surface, thereby creating a stable anchorage of the prosthesis, both short and long term.

A hip prosthesis consists of 3 main elements:

  1. socket
  2. ball
  3. femoral component, which hold ball. Femoral component is anchored to the upper end of the femur including the upper 12-15 cm of the marrow cavity.

Achieved good results with this principle. The method involves a risk of fracture at the top end of the femur bone during and after insertion of the prosthesis, but also that there is some bone loss in the year after surgery. Finally there is a 3-10% chance that you get thigh pain due to different elasticity of the femur and the long shank prosthesis.

Based on the foregoing disadvantages of the femoral components, which are commonly used, has for years been experimenting with the introduction of shorter implants, which are either anchored in the femoral neck or femoral neck combined with the very top end of the femur bone (metaphysis). By using such a prosthesis, it is proven to preserve the bone in the upper femur forward and avoids the disadvantage in terms of the above described femoral pain. There is also described problems by using these short prostheses, especially in the form of solution, and pain secondary to anchor bolts in the upper femur forward.

In Orthopaedic Surgery, Region Nordjylland, one has in the period 1999 to 2003 33 such prostheses implanted at clinics in Farsø and Frederikshavn and achieved good results apart from pain similar to the above anchoring screws. At follow-up of these prostheses, using DEXA scans, the investigators have shown that prosthesis, bone-saving, since bone mass at the femoral neck and the very top end of the femur bone is preserved.

From our experience with the aforementioned short prosthesis, the investigators have joined with Biomechanical Institute, Royal National Orthopaedic Hospital, Stanmore, London and firm Biomet developed a modern design of the above. This is a short prosthesis that is anchored in the femoral neck and the upper end of the femur (metaphysis). Prosthesis made of titanium with a porous surface (Bonemaster ®). The prosthesis is anchored during surgery by pressure-fit (press-fit) and in a few weeks the bone grows into the prosthesis.

Prosthesis manufactured in 5 sizes and design of the prosthesis is aligned with a series of CT scans of the femur was carried out at Stanmore in London. Has developed instruments to ensure a uniform instrumentation and minimizing the risk of fractures in connection with the operation. Performed a series of laboratory tests and these tests, the prosthesis was found to be completely stable and even full load stable and the risk of fracture related to prosthesis insertion is minimized.

The current study intends to examine whether that can be achieved equally good clinical results as with the conventional uncemented femoral component and bone mass in the upper end of the femur bone is preserved. Using a specific X-ray analysis (RSA) also assessed the stability between the prosthesis and bone. Both DEXA scan as RSA studies have routine examinations by Orthopaedic Surgery, Region Nordjylland, Klinik Farsø.

The planned surgery 50 young men and women with primary or secondary osteoarthritis of the hip joint. Patients fulfilling the inclusion criteria and not subject to exclusion criteria received oral and written information about the investigation.

Accept the patient to cooperate with the investigation confirmed that the patient's signature approx. 2 weeks after oral and written information is given.

The operation is performed after the usual principles with rear access to the hip joint, removal of rod ends and the insertion of an uncemented socket. After preparing the femoral neck and top of thigh to the insertion of the short femur prosthesis and make selection using tantalumkugler for RSA analysis. When the prosthesis is inserted carried out sample-space theorem and using a 36 mm Co-Cr-ball, which is currently the department's practices. After surgery the patient allowed partial load the first 6 weeks. There is an ongoing clinical and radiographic controls and registration of unforeseen events arising from the use of the product.

If the flow after 2 years are fully comparable clinical outcomes, minimal migration as measured by RSA and final preservation of the bone around the implant, then the use of the implant extends to several clinics at home and abroad, as per the recommendations of the Danish Orthopaedic Association reference program for hip replacement surgery.

When implementing any new implant designs is a lower risk of unforeseen complications in the form of fracture encountered in denture-deployment and subsequent unexpected prosthetic solution. If the burst occurs Intraoperative, you can convert to the deployment of conventional hip prosthesis without involving major risks for the patient. Early prosthetic solution is also possible deployment of conventional complete dentures without result deteriorates. The disadvantages of the possible complications are in the worst case of operation (revision).

In addition, the disadvantages of trial participation increased radiation dose due to 4 additional X-ray checks in the first 2 years after surgery and 4 extra bone scans (DEXA).

The described investigation will clarify whether the theoretical advantages that have hitherto been demonstrated by clinical and biomechanical study (normal weight transfer, bone sparing and bone-keeping in the short and long term), also obtained by applying the newly developed prosthetic component. If so, there will then be able to especially younger patients with osteoarthritis of the hip joints better chance of achieving good clinical outcomes and long-term sustainability by eventual replacement surgery, typically 10-20 years after primary surgery.

Disadvantages of the described study estimated minimal compared to the benefits that a large group of patients could benefit.

The actual cost of conducting the survey shall be borne by the prosthesis manufacturer Biomet UK Ltd.. and Orthopaedic Surgery, North Jutland and the amount transferred to specific research account affiliated research unit of Orthopaedic Surgery, Region Nordjylland and paid through the Budget and Finance, Region House, Region Nordjylland.

Conditions
Coxarthrosis
Being tested
Primoris
Keywords
THA
Medical subject headings
Osteoarthritis, Hip

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PrimorisDevice

    Total hip arthroplasty with the new Primoris femoral component

Study groups in NCT01326832
Study groupRoleWhat they receive
Primoris50 patients included in RSA cohort of total of 350 anticipated Primoris cases
Receives: Device: Primoris

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. RSA

    radio stereographic analysis for prosthesis migration

    Measured: 2 years

Secondary outcomes (2)
  1. Harris Hip score

    Harris Hip score, Harris Hip Score, 0-100 points. The higher the positive difference between baseline and follow up the better the result.

    Measured: 10 years

  2. Western Ontario and McMaster Universities Arthritis Index (WOMAC)

    Womac has 3 subscales: Pain score range 0-20, Stiffness score range 0-8, Physical Function score range 0-68. Higher scores on the WOMAC indicate worse pain, stiffness, and functional limitations.

    Measured: 10 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted31 Mar 2011 (estimated)
  2. Study startSep 2011
  3. Primary completionDec 2022
  4. Study completionDec 2024 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
350 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01326832
Sponsor's protocol ID
BMETEU.CR.UK4A
Acronym
Primoris
Status last verified
Jun 2024
First submitted
30 Mar 2011
Last updated
1 Jul 2024
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Coxarthrosis, run by Zimmer Biomet at 2 sites in Denmark.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 1 inclusion and 17 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 1 Jul 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 2 sites in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

RSA (time frame: 2 years). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 1 Jul 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in